Eton Pharmaceuticals, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing reports annual results, not standalone fourth-quarter results. Filed March 16, 2022.
Business context
Eton develops, acquires, and commercializes specialty pharmaceutical products, with a focus on orphan drugs and hospital injectables. It reported a portfolio of 11 products and candidates; six products had been approved and commercially launched. The business relies on third-party manufacturers and commercialization partners for several products.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net revenue | $21.832 million | $0.039 million |
| Gross profit (loss) | $19.209 million | $(0.247) million |
| Gross margin | Approximately 88% | Not meaningful given minimal revenue and gross loss |
| Research and development | $6.235 million | $14.104 million |
| General and administrative | $14.469 million | $12.760 million |
| Net loss | $(1.955) million | $(27.970) million |
| Basic and diluted loss per share | $(0.08) | $(1.33) |
| Operating cash flow | $(4.721) million | $(22.346) million |
FY2021 revenue included $19.0 million of licensing revenue, primarily a $17.0 million milestone payment for the neurology products sold to Azurity. Product sales and royalties were $2.832 million. The reported gross profit included $1.5 million of cost of sales associated with licensing revenue. Operating loss was $1.495 million.
At year-end, cash and cash equivalents were $14.406 million, working capital was $19.0 million, total assets were $27.465 million, and total liabilities were $9.835 million. Debt carrying value was approximately $6.680 million, including $1.418 million current and $5.262 million long-term; gross SWK loan principal was $7.0 million. The loan is secured by company assets and requires a minimum cash balance of $3.0 million.
Cash used in investing activities was $2.559 million, including $3.250 million paid for Carglumic Acid rights, partly offset by $0.700 million from selling laboratory equipment. Financing cash flow was $0.391 million. Cash declined by $6.889 million during the year.
Changes versus the prior year
- Revenue rose from $0.039 million to $21.832 million, mainly due to the Azurity transaction and milestones; product sales also increased as launches progressed.
- Gross profit improved from a loss of $0.247 million to $19.209 million. Management attributed the prior-year loss partly to Biorphen price discounts and inventory reserves.
- Net loss narrowed by $26.015 million. R&D expense fell $7.869 million, primarily because significant product-development milestone payments in 2020 did not recur; G&A rose $1.709 million with personnel and professional-services spending.
- Operating cash use decreased, but cash fell from $21.295 million to $14.406 million as operating and investment outflows exceeded financing inflows.
Outlook, risks, and unusual items
- Management expected growth from existing products and further launches, but provided no numerical revenue or earnings guidance. It stated that year-end cash, product revenues, and anticipated milestones were expected to fund operations for at least 12 months. The estimate included a $5.0 million EPRONTIA launch milestone received in January 2022 and depends on sales and spending assumptions.
- Pipeline and launch milestones included Rezipres launch in March 2022; anticipated FDA submission for ZENEO hydrocortisone autoinjector in 2023; and expected Canadian Alkindi Sprinkle submission in 2022. Dehydrated alcohol injection had received an FDA Complete Response Letter in May 2021. Zonisamide’s manufacturing site was inspected in January 2022 after a COVID-related delay; lamotrigine had a May 30, 2022 PDUFA date.
- Eton reported a $1.414 million slow-moving Biorphen inventory reserve at year-end, up from $0.623 million in 2020, reflecting expiry risk. Management also said Biorphen had generated gross losses in 2021 and 2020 due to slower-than-expected sales and price reductions.
- Other 2021 items included a $0.365 million gain from PPP loan forgiveness and a $0.181 million gain on equipment sale. The company closed its R&D laboratory in May 2021 and outsourced development needs.
- Key risks include regulatory delays or rejection, reliance on third-party manufacturers and partners, COVID-related disruption, reimbursement and drug-pricing pressure, product adoption, patent litigation, and potential future financing needs and dilution. Eton also disclosed related-party arrangements, including a CEO interest in a former product partner. No material pending or threatened litigation was reported in the legal-proceedings disclosure; the filing separately describes ongoing Cysteine Paragraph IV patent litigation.
- The auditor issued an unqualified opinion on the financial statements. Its critical audit matter was estimation of product-sales deductions, including returns and chargebacks, given limited sales history and management judgment. The auditor did not attest to internal-control effectiveness; management concluded controls were effective.
Important facts for investors to verify
- How much recurring product revenue and royalty income supports the business apart from licensing milestones, and whether further Azurity milestones are achieved.
- Whether commercial uptake, pricing, and reimbursement improve for Biorphen, Alkindi Sprinkle, Carglumic Acid, and Rezipres, including the effect of Biorphen inventory reserves and returns.
- Current cash, debt repayment requirements, and whether management’s stated 12-month funding runway remains valid after the January 2022 milestone receipt.
- Regulatory and litigation developments for the filed and planned candidates, particularly dehydrated alcohol, zonisamide, lamotrigine, and Cysteine.
- Potential effects of partner economics, related-party agreements, and additional equity financing on Eton’s cash flows and shareholder dilution.